| Drug General Information |
| Drug ID |
D01MBF
|
| Former ID |
DNC010035
|
| Drug Name |
4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H17F2NO
|
| Canonical SMILES |
C1CNCCC1C2=C(C=CC=C2F)OC3=CC=C(C=C3)F
|
| InChI |
1S/C17H17F2NO/c18-13-4-6-14(7-5-13)21-16-3-1-2-15(19)17(16)12-8-10-20-11-9-12/h1-7,12,20H,8-11H2
|
| InChIKey |
WPYMMOOTBZOFOZ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Sodium-dependent noradrenaline transporter |
Target Info |
Inhibitor |
[1]
|
|---|
| Sodium-dependent serotonin transporter |
Target Info |
Inhibitor |
[1]
|
| 5-hydroxytryptamine 1A receptor |
Target Info |
Inhibitor |
[1]
|
| Sodium-dependent dopamine transporter |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Serotonergic synapsehsa04024:cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Serotonergic synapsehsa04728:Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Alcoholism
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesisP04373:5HT1 type receptor mediated signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
5HT3 type receptor mediated signaling pathway
|
|
5HT4 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
|
Parkinson disease
|
|
Dopamine receptor mediated signaling pathway
|
|
Pathway Interaction Database
|
Alpha-synuclein signaling
|
|
Reactome
|
Na+/Cl- dependent neurotransmitter transportersR-HSA-390666:Serotonin receptors
|
|
G alpha (i) signalling eventsR-HSA-442660:Na+/Cl- dependent neurotransmitter transporters
|
|
WikiPathways
|
Monoamine Transport
|
|
NRF2 pathway
|
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport
|
|
SIDS Susceptibility Pathways
|
|
Synaptic Vesicle Pathway
|
|
Serotonin Transporter ActivityWP722:Serotonin HTR1 Group and FOS Pathway
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP727:Monoamine Transport
|
|
Dopaminergic Neurogenesis
|
|
Parkinsons Disease Pathway
|
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
|
|
Neurotransmitter Clearance In The Synaptic Cleft
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists. |
|---|
